Suppr超能文献

胸主动脉腔内修复术后急慢性B型主动脉夹层患者的临床结局及生活质量

Clinical outcomes and quality of life in patients with acute and subacute type B aortic dissection after thoracic endovascular aortic repair.

作者信息

Bi Yonghua, Yi Mengfei, Han Xinwei, Ren Jianzhuang

机构信息

Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

出版信息

J Int Med Res. 2020 Aug;48(8):300060520945506. doi: 10.1177/0300060520945506.

Abstract

OBJECTIVE

Thoracic endovascular aortic repair (TEVAR) is considered the mini-invasive treatment of choice for patients with Stanford type B aortic dissection (TBAD). This study aimed to investigate the clinical outcomes and quality of life (QoL) in patients with acute and subacute TBAD after TEVAR.

METHODS

From January 2014 until July 2016, 22 acute patients (Group A) and 18 subacute patients received TEVAR (Group B), and 13 patients were managed non-operatively (Group C). The Medical Outcomes Study Short Form-36 was used to assess QoL preoperatively and after TEVAR. Operative techniques and complications were retrospectively analyzed.

RESULTS

The role emotion, vitality, and mental health domains scored well preoperatively. Except for role emotion, vitality, and mental health, the remaining domains significantly improved after TEVAR. There was no significant difference in QoL metrics between Groups A and B. In Group C, bodily pain and social functioning domains were improved, and role emotion was decreased, with no improvement in the remaining domains. The 3-year survival rates were 95.5%, 100%, and 85.7% for Groups A, B, and C, respectively.

CONCLUSIONS

TEVAR may be safe and effective in patients with acute and subacute TBAD with similar and favorable clinical and QoL metrics.

摘要

目的

胸主动脉腔内修复术(TEVAR)被认为是斯坦福B型主动脉夹层(TBAD)患者的微创治疗选择。本研究旨在调查急性和亚急性TBAD患者接受TEVAR后的临床结局和生活质量(QoL)。

方法

2014年1月至2016年7月,22例急性患者(A组)和18例亚急性患者接受了TEVAR(B组),13例患者接受非手术治疗(C组)。采用医学结局研究简表36评估术前及TEVAR术后的生活质量。对手术技术和并发症进行回顾性分析。

结果

角色情感、活力和心理健康领域术前得分良好。除角色情感、活力和心理健康外,TEVAR术后其余领域均有显著改善。A组和B组在生活质量指标上无显著差异。C组中,身体疼痛和社会功能领域有所改善,角色情感下降,其余领域无改善。A、B、C组的3年生存率分别为95.5%、100%和85.7%。

结论

TEVAR对于急性和亚急性TBAD患者可能是安全有效的,临床和生活质量指标相似且良好。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6672/7418244/4e63ccc67a5b/10.1177_0300060520945506-fig1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验